Search results
Showing 1 to 4 of 4 results for teduglutide
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)
This guidance has been updated and replaced by NICE technology appraisal guidance TA804.
NICE recommends treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.